2005-2010年不动杆菌属感染及耐药性检测

Acinetobacter infections and their drug resistance from 2005 to 2010

目的了解医院2005-2010年不动杆菌属的耐药性变迁。方法采用VITEK-60全自动微生物分析仪对菌株鉴定及药敏检测,药敏结果使用WHONET软件进行分析。结果 ICU中分离到的不动杆菌属最多,占68.6%,痰液中分离到的菌株最多,占65.6%;6年中分离到的不动杆菌属逐年增长;对三代喹诺酮、哌拉西林/他唑巴坦及亚胺培南的敏感率高,均>89.0%,氨曲南对不动杆菌属的耐药率为66.0%～90.1%。结论氨曲南不适合不动杆菌属感染的治疗,宜首选三代喹诺酮、哌拉西林/他唑巴坦,次选亚胺培南,医师应根据药理学特点,选择合适抗菌药物。

OBJECTIVE To understand the change of drug resistance of Acinetobacter from 2005 to 2010. METHODS By the means of VITEK60 automated microbial analyzer, the identification and drug susceptibility testing for the isolates were performed. The result of susceptibility testing was analyzed using WHONET software. RESULTS The bacteria were mainly isolated from ICU, ,accounting for 68.6 %, and the strains isolated from sputum accounted for 65.6%. There was an increasing trend in the number of the isolates during the six years. The isolated bacteria were highly susceptible to the third generation of quinolones, piperacillin/tazobactam, and imipenem, with the susceptibility rates higher than 89. 0%, the drug resistance rate of Acinetobacter to aztreonam varied from 66.0% to 90.1%. CONCLUSION Aztreonam is not suitable for the treatment of Acineto bacter infections, the third generation of quinolones is the most preferred, followed by the imipenem. Clinician should select the aot^roDriate antibiotics based on the pharmacological characteristics.